IDM, Inc. Announces Detailed Phase III Results For Mepact In Osteosarcoma To Be Presented At ASPHO Annual Meeting
10/19/2005 5:10:20 PM
PARIS--(BUSINESS WIRE)--May 11, 2005--IDM (Immuno-Designed Molecules), a privately held biopharmaceutical company which shareholders recently entered into an agreement to combine with Epimmune Inc. (Nasdaq:EPMN), announces that the Phase III clinical results for its Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine product (L-MTP-PE), also named Mepact(TM), will be presented and discussed in a panel symposium on May 16 in Washington, DC.
Presentations will be made by Dr. Paul A. Meyers (Memorial Sloan-Kettering Cancer Center), the study's principal investigator and Dr. Eugenie S. Kleinerman (The University of Texas M. D. Anderson Cancer Center). Other panel members include Dr. Richard Gorlick (The Children's Hospital at Montefiore), Dr. Edmund A. Gehan (Lombardi Comprehensive Cancer Center at Georgetown University), and Dr. Neyssa Marina (Stanford University Medical Center). The presentations and panel discussion will take place during the Annual Meeting of the American Society of Pediatric Hematology/Oncology (ASPHO), in Washington, DC at the Renaissance Hotel on May 16 from 12:45 to 2:45 p.m.
comments powered by